Functional and structural perspectives on allosteric modulation of GPCRs

Current Opinion in Cell Biology

Volumn 27, Issue 1, 2014, Pages 94-101

  Langmead, Christopher J ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND;

ALLOSTERISM; ANALYTICAL PARAMETERS; BINDING SITE; MODULATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890733611     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.11.007     Document Type: Review

References (40)

1. DeLean A., Lefkowitz R.J. Dihydroergocryptine binding and alpha-adrenoreceptors in smooth muscle. Nature 1980, 283:109-110.
2. Monod J., Wyman J., Changeux J.P. On the nature of allosteric transitions: a plausible model. J Mol Biol 1965, 12:88-118.
3. Stockton J.M., Birdsall N.J., Burgen A.S., Hulme E.C. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983, 23:551-557.
4. Mathiesen J.M., Svendsen N., Brauner-Osborne H., Thomsen C., Ramirez M.T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 2003, 138:1026-1030.
5. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezeau L., Carroll F., Pin J.P., et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 2000, 275:33750-33758.
6. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 2000, 58:1412-1423.
7. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., McLean A., McIntosh L., Goodwin G., Walker G., et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005, 68:1484-1495.
8. Ehlert F.J. Analysis of allosterism in functional assays. J Pharmacol Exp Ther 2005, 315:740-754.
9. Leach K., Sexton P.M., Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 2007, 28:382-389.
10. Langmead C.J. Determining allosteric modulator mechanism of action: integration of radioligand binding and functional assay data. Methods Mol Biol 2011, 746:195-209.
11. Bradley S.J., Langmead C.J., Watson J.M., Challiss R.A. Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol 2011, 79:874-885.
12. Leach K., Loiacono R.E., Felder C.C., McKinzie D.L., Mogg A., Shaw D.B., Sexton P.M., Christopoulos A. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 2010, 35:855-869.
13. Valant C., Felder C.C., Sexton P.M., Christopoulos A. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Mol Pharmacol 2012, 81:41-52.
14. Litschig S., Gasparini F., Rueegg D., Stoehr N., Flor P.J., Vranesic I., Prezeau L., Pin J.P., Thomsen C., Kuhn R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 1999, 55:453-461.
15. Langmead C.J., Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 2006, 27:475-481.
16. Noetzel M.J., Rook J.M., Vinson P.N., Cho H.P., Days E., Zhou Y., Rodriguez A.L., Lavreysen H., Stauffer S.R., Niswender C.M., et al. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 2012, 81:120-133.
17. Wootten D., Simms J., Miller L.J., Christopoulos A., Sexton P.M. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A 2013, 110:5211-5216.
18. Kenakin T.P., Beek D. Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships. J Pharmacol Exp Ther 1980, 213:406-413.
19. Langmead C.J. Ligand properties and behaviours in an allosteric age. Trends Pharmacol Sci 2012, 33:621-622.
20. Canals M., Lane J.R., Wen A., Scammells P.J., Sexton P.M., Christopoulos A. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem 2012, 287:650-659.
21. Kenakin T., Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013, 12:205-216.
22. Abdul-Ridha A., Lane J.R., Sexton P.M., Canals M., Christopoulos A. Allosteric modulation of a chemogenetically modified G protein-coupled receptor. Mol Pharmacol 2013, 83:521-530.
23. Huynh T.V.C., Crosby I.T., Sexton P.M., Christopoulos A., Capuano B. Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. J Med Chem 2013.
24. Davey A.E., Leach K., Valant C., Conigrave A.D., Sexton P.M., Christopoulos A. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology 2012, 153:1232-1241.
25. Lane J.R., Sexton P.M., Christopoulos A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 2013, 34:59-66.
26. Steinfeld T., Mammen M., Smith J.A., Wilson R.D., Jasper J.R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 2007, 72:291-302.
27. Antony J., Kellershohn K., Mohr-Andra M., Kebig A., Prilla S., Muth M., Heller E., Disingrini T., Dallanoce C., Bertoni S., et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 2009, 23:442-450.
28. Narlawar R., Lane J.R., Doddareddy M., Lin J., Brussee J., Ijzerman A.P. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem 2010, 53:3028-3037.
29. Valant C., Gregory K.J., Hall N.E., Scammells P.J., Lew M.J., Sexton P.M., Christopoulos A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 2008, 283:29312-29321.
30. Venkatakrishnan A.J., Deupi X., Lebon G., Tate C.G., Schertler G.F., Babu M.M. Molecular signatures of G-protein-coupled receptors. Nature 2013, 494:185-194.
31. Gregory K.J., Nguyen E.D., Reiff S.D., Squire E.F., Stauffer S.R., Lindsley C.W., Meiler J., Conn P.J. Probing the metabotropic glutamate receptor 5 (mGlu(5)) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a 'molecular switch' in PAM pharmacology. Mol Pharmacol 2013, 83:991-1006.
32. Leach K., Davey A.E., Felder C.C., Sexton P.M., Christopoulos A. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Mol Pharmacol 2011, 79:855-865.
33. Nawaratne V., Leach K., Felder C.C., Sexton P.M., Christopoulos A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 2010, 285:19012-19021.
34. Lundstrom L., Bissantz C., Beck J., Wettstein J.G., Woltering T.J., Wichmann J., Gatti S. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol 2011, 164:521-537.
35. Tan Q., Zhu Y., Li J., Chen Z., Han G.W., Kufareva I., Li T., Ma L., Fenalti G., Li J., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013, 341:1387-1390.
36. Hollenstein K., Kean J., Bortolato A., Cheng R.K., Dore A.S., Jazayeri A., Cooke R.M., Weir M., Marshall F.H. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013, 499:438-443.
37. Dror R.O., Green H.F., Valant C., Borhani D.W., Valcourt J.R., Pan A.C., Arlow D.H., Canals M., Lane J.R., Rahmani R., et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 2013, 84:295-299.
38. Haga K., Kruse A.C., Asada H., Yurugi-Kobayashi T., Shiroishi M., Zhang C., Weis W.I., Okada T., Kobilka B.K., Haga T., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482:547-551.
39. Kruse A.C.R.A., Manglik A., Hu J., Hu K., Eitel K., Hubner H., Pardon E., Valant C., Sexton P.M., Christopoulos A., Felder C.C., Gmeiner P., Steyaert J., Weis W.I., Garcia K.C., Wess J., Kobilka B.K. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 2013, 504:101-106.
40. Urwyler S., Pozza M.F., Lingenhoehl K., Mosbacher J., Lampert C., Froestl W., Koller M., Kaupmann K. N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 2003, 307:322-330.